Details of issuance or disposal
Issuance of Euro-Yen convertible bonds with stock acquisition rights due 2029 and Euro-Yen convertible bonds with stock acquisition rights due 2031
The total amount of the proceeds and the estimated net proceeds are Not disclosed.
Not calculated because the conversion price has not yet been determined
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of Euro-Yen convertible bonds with stock acquisition rights due 2029 and Euro-Yen convertible bonds with stock acquisition rights due 2031 |
| Issue price and disposal price | The payment amount for the bonds will be at least 100.0% of the principal amount, and the offering price will be at least 102.5% of the principal amount. The specific amounts have not been determined. |
| Amount of funds to be raised | The total amount of the proceeds and the estimated net proceeds are Not disclosed. |
| Specific use of funds | Details Funds for the self-tender offer / Amount The total amount required for the self-tender offer (to be determined based on the tender offer price and the number of shares tendered) / Scheduled timing of expenditures By the end of July 2026, Details Expansion of major manufacturing facilities for sputtering targets for semiconductors, capacity expansion for increased production of crystal materials, and acquisition of rare-metal resources for the Focus Businesses, among other purposes / Amount The amount remaining after allocation to the funds for the self-tender offer / Scheduled timing of expenditures By the end of March 2028 |
| Payment date | 3 June 2026 (London time) |
| Dilution Rate | Not calculated because the conversion price has not yet been determined |
| Total number of issued shares | 928,463,102 shares (as of 31 March 2026) → Not disclosed |
| Basis for determining the amount to be paid | The payment amount for the bonds will be determined after taking into account investor demand and other market conditions, and will not be less than 100.0% of the principal amount. The offering price will not be less than 102.5% of the principal amount. The initial conversion price will be 1.2 times the closing price of the Company's common shares immediately before the execution of the underwriting agreement, representing a 20% premium. |
| Exercise price | The initial conversion price will be 1.2 times the closing price immediately before the execution of the underwriting agreement. It will be adjusted in the event of an issuance or disposal of shares at a payment amount below the market price, a stock split or consolidation, certain dividend payments, or other specified events. The floor has not been disclosed. |
| Exercise period | Due 2029 From 17 June 2026 through 21 May 2029 (London time) / Due 2031 From 17 June 2026 through 20 May 2031 (London time) |
| Number of Stock Acquisition Rights | 12,500 stock acquisition rights for each series, plus the number of stock acquisition rights relating to the bonds with stock acquisition rights issued as replacements. The number of unexercised rights has not been disclosed. |
| Underwriter / lead underwriter | Daiwa Capital Markets Europe Limited, Nomura International plc, Morgan Stanley & Co. International plc, Merrill Lynch International, J.P. Morgan Securities plc, Goldman Sachs International |
| Procedures under the Corporate Code of Conduct | The issuance was resolved at the Board of Directors meeting held on 11 May 2026. Not disclosed with respect to obtaining an opinion from an independent third party and confirming shareholders' intentions. |
| Most recent equity financing | No applicable matters |
| Impact on Business Performance | There is no change to the earnings forecast for the current fiscal year. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purposes are to ensure flexibility in capital policy, address ENEOS Holdings' intention to sell its shares, avoid a temporary large-scale release of shares into the market, secure funds for growth investment, and limit the impact on the Company's financial position.